Metabolic Influence of S. boulardii and S. cerevisiae in Cross-Kingdom Models of S. mutans and C. albicans
Ting Li,
No information about this author
Xingyi Lu,
No information about this author
Yan Wu
No information about this author
et al.
Journal of Fungi,
Journal Year:
2025,
Volume and Issue:
11(4), P. 325 - 325
Published: April 19, 2025
Recent
studies
highlight
the
potential
of
Saccharomyces
species
as
probiotics
due
to
their
ability
modulate
microbial
interactions
and
reduce
cariogenic
activity,
yet
underlying
metabolic
mechanisms
remain
unclear.
This
study
investigates
cross-kingdom
effects
boulardii
cerevisiae
on
processes
Streptococcus
mutans
Candida
albicans
using
a
metabolomics-based
approach.
Untargeted
LC-MS/MS
analysis
was
conducted
assess
metabolites
in
planktonic
model,
followed
by
metabolomic
profiling
pathway
identify
key
alterations.
The
results
revealed
that
S.
demonstrated
regulatory
C.
albicans.
Specifically,
down-regulated
262
up-regulated
168,
while
265
168.
Both
yeast
carbohydrate
amino
acid
metabolism
albicans,
resulting
reduced
biomolecule
synthesis
less
acidic
environment.
also
certain
processes,
including
purine
metabolism,
suggesting
compensatory
mechanism
for
nucleotide
synthesis.
Notably,
dual
were
observed,
where
specific
simultaneously
down-regulated,
indicating
complex
crosstalk.
These
findings
suggest
both
through
shared
mechanism,
offering
potentials
dental
caries
prevention.
Language: Английский
Reliability of Matrix‐Assisted Laser Desorption‐Ionisation Time‐of‐Flight Mass Spectrometry as a Method for Drug‐Resistant Tuberculosis Gene Identification
Kaishun Zhao,
No information about this author
Wei Wei,
No information about this author
Lijia Yang
No information about this author
et al.
Clinical and Experimental Pharmacology and Physiology,
Journal Year:
2025,
Volume and Issue:
52(6)
Published: April 24, 2025
ABSTRACT
Instances
of
drug‐resistant
tuberculosis
(TB),
particularly
multidrug‐
and
extensive
TB,
are
escalating
worldwide;
therefore,
there
is
an
urgent
need
to
explore
suitable
treatment
strategies.
This
study
assessed
the
precision
matrix‐assisted
laser
desorption‐ionisation
time‐of‐flight
mass
spectrometry
(MALDI‐TOF
MS)
in
detecting
TB.
We
developed
a
multiplex
MALDI‐TOF
MS
detection
assay
that
concurrently
identifies
51
gene
mutations
for
six
commonly
used
medications:
rifampicin
(RFP),
isoniazid
(INH),
levofloxacin
(LVX),
moxifloxacin
(MOX),
capreomycin
(CPM)
amikacin
(AMK).
Subsequently,
we
evaluated
accuracy
system
by
testing
clinical
sputum
samples
with
known
(
n
=
45)
unknown
254)
minimum
inhibitory
concentrations
(MICs),
using
Sanger‐sequenced
genes
as
references.
The
exhibited
sensitivity
88.00%
specificity
95.24%
45
isolates.
Similarly,
254
samples,
demonstrated
associated
each
medication
follows:
RFP—sensitivity:
98.97%,
specificity:
99.36%;
INH—sensitivity:
97.80%,
100.00%;
LVX
MOX—sensitivity:
97.14%,
AMK
CPM—sensitivity:
100.00%,
100.00%.
also
displayed
favourable
values
MIC
validation
92.39%,
92.59%;
75.21%,
99.27%;
LVX—sensitivity:
75.28%,
99.39%;
73.24%,
91.26%;
AMK—sensitivity:
94.87%,
96.74%;
89.47%,
95.83%.
Meanwhile,
our
allows
identification
Mycobacterium
complex
(MTBC).
remarkable
making
it
potential
alternative
approach
TB
diagnosis.
Language: Английский